Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Proteinuria

ClinicalTrials.gov lists 445 trials for Proteinuria or a narrower condition beneath it. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has the most among industry and government lead sponsors, with 16.

MeSH D011507 Urogenital Diseases C12 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 15 Phase 1/2 Phase 1/2 3 Phase 2 Phase 2 90 Phase 2/3 Phase 2/3 10 Phase 3 Phase 3 56 Phase 4 Phase 4 94 Not applicable Not applicable 86 Observational Observational 91 Phase 1 Phase 1 15 Phase 1/2 Phase 1/2 3 Phase 2 Phase 2 90 Phase 2/3 Phase 2/3 10 Phase 3 Phase 3 56 Phase 4 Phase 4 94 Not applicable Not applicable 86 Observational Observational 91

Trials per phase (log scale)

318 of the 445 trials are tagged with Proteinuria itself; the rest are tagged with a narrower condition beneath it.

Get the Proteinuria report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Proteinuria trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 26

1994: 2 trials (Observational 2) 1996: 3 trials (Observational 1, Not applicable 1, Phase 4 1) 1997: 1 trials (Phase 4 1) 1998: 2 trials (Not applicable 1, Phase 4 1) 1999: 2 trials (Phase 3 1, Phase 2 1) 2000: 4 trials (Observational 1, Phase 4 1, Phase 2 1, Phase 1/2 1) 2001: 2 trials (Observational 2) 2002: 8 trials (Not applicable 1, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 1) 2003: 10 trials (Not applicable 2, Phase 4 3, Phase 3 5) 2004: 8 trials (Not applicable 3, Phase 4 3, Phase 2 1, Phase 1/2 1) 2005: 15 trials (Observational 3, Not applicable 6, Phase 4 4, Phase 3 1, Phase 2 1) 2006: 17 trials (Observational 2, Not applicable 4, Phase 4 3, Phase 3 2, Phase 2/3 2, Phase 2 3, Phase 1 1) 2007: 24 trials (Observational 7, Not applicable 3, Phase 4 4, Phase 3 4, Phase 2/3 2, Phase 2 4) 2008: 19 trials (Observational 6, Not applicable 2, Phase 4 6, Phase 3 1, Phase 2 3, Phase 1 1) 2009: 24 trials (Observational 4, Not applicable 5, Phase 4 10, Phase 3 2, Phase 2 2, Phase 1 1) 2010: 16 trials (Observational 6, Not applicable 3, Phase 4 4, Phase 3 1, Phase 2 2) 2011: 20 trials (Observational 4, Not applicable 2, Phase 4 6, Phase 3 1, Phase 2 6, Phase 1 1) 2012: 17 trials (Observational 3, Not applicable 3, Phase 4 5, Phase 3 2, Phase 2 4) 2013: 26 trials (Observational 3, Not applicable 6, Phase 4 3, Phase 3 4, Phase 2 9, Phase 1 1) 2014: 18 trials (Observational 5, Not applicable 3, Phase 4 6, Phase 3 2, Phase 2 2) 2015: 18 trials (Observational 3, Not applicable 1, Phase 4 4, Phase 3 2, Phase 2/3 2, Phase 2 3, Phase 1 3) 2016: 15 trials (Observational 3, Not applicable 2, Phase 4 2, Phase 3 4, Phase 2 2, Phase 1 2) 2017: 18 trials (Observational 3, Not applicable 3, Phase 4 1, Phase 3 3, Phase 2 7, Phase 1 1) 2018: 22 trials (Observational 4, Not applicable 5, Phase 4 3, Phase 3 4, Phase 2 6) 2019: 15 trials (Observational 4, Not applicable 5, Phase 4 1, Phase 2 4, Phase 1 1) 2020: 10 trials (Observational 1, Not applicable 3, Phase 4 3, Phase 3 1, Phase 2 2) 2021: 18 trials (Observational 6, Not applicable 2, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1/2 1) 2022: 14 trials (Observational 2, Not applicable 3, Phase 3 3, Phase 2 5, Phase 1 1) 2023: 21 trials (Observational 6, Not applicable 7, Phase 4 4, Phase 3 1, Phase 2 3) 2024: 14 trials (Observational 2, Not applicable 3, Phase 4 3, Phase 3 1, Phase 2 5) 2025: 18 trials (Observational 4, Not applicable 2, Phase 4 3, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 23
2025 18
2024 14
2023 21
2022 14
2021 18
2020 10
2019 15
2018 22
2017 18

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 25 trials starting in 2026 and about 21 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 32 months from start to primary completion across 36 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 279 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Proteinuria trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 15
Phase 1/2 3
Phase 2 90
Phase 2/3 10
Phase 3 56
Phase 4 94
Not applicable 86
Observational 91

How many Proteinuria trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 15
Recruiting 40
Enrolling by invitation 3
Active, not recruiting 11
Completed 256

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Proteinuria trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 16
Novartis Pharmaceuticals 11
Alexion Pharmaceuticals, Inc. 6
AstraZeneca 6
Novartis 6

Which drugs are being tested for Proteinuria? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
BMS-512148 15
Finerenone 11
RITUXIMAB 8
VALSARTAN 8
Iptacopan 6

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Low dose losartan 19
Empagliflozine 9
Aliskiren 150 9
Acthar low dose (40 U) 7
Tbl amiloride 5

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Proteinuria trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 91 11
Angina Unstable 85 2
Malignant cancer 79 1
SAE by System Organ 75 1
Cardiac Failure 68 4

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Proteinuria? (694)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Atrasentan in Patients with IgA Nephropathy. The New England journal of medicine 2025 Yes
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. The New England journal of medicine 2025 Yes
Predictors of proteinuria, amyloidosis and kidney failure in familial Mediterranean fever: data from the International AIDA Network Registry. Rheumatology (Oxford, England) 2025 Yes
Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis. Pediatric nephrology (Berlin, Germany) 2025 Yes
Correlation between thyroid function and proteinuria in patients with chronic kidney disease stages 3 and 4. International urology and nephrology 2025 Yes

Showing 5 of 694 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages